J. Safra Sarasin Holding AG Sells 123,322 Shares of Pfizer Inc. (NYSE:PFE)

J. Safra Sarasin Holding AG cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 68.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,571 shares of the biopharmaceutical company's stock after selling 123,322 shares during the period. J. Safra Sarasin Holding AG's holdings in Pfizer were worth $1,474,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the fourth quarter valued at about $31,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock traded up $0.41 during mid-day trading on Thursday, reaching $22.80. 34,965,876 shares of the company's stock were exchanged, compared to its average volume of 40,601,473. The business's fifty day simple moving average is $24.63 and its 200 day simple moving average is $26.01. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $129.31 billion, a PE ratio of 16.17, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company's revenue for the quarter was up 24.7% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is currently 121.99%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PFE shares. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, UBS Group decreased their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $29.57.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.